Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prilosec OTC loses patent extension

This article was originally published in The Tan Sheet

Executive Summary

The U.S. Patent and Trademark Office dismisses AstraZeneca's application to extend a key product patent for the OTC proton pump inhibitor it licenses to Procter & Gamble. The agency explains in a Dec. 16 letter that Prilosec OTC is ineligible for a patent term extension because it was not the first instance of commercial marketing for the underlying active ingredient and because its application was submitted in an untimely fashion. The Prilosec OTC patent expires Oct. 6, 2015, according to FDA's Orange Book of approved drug products. An AstraZeneca spokesman says the firm is "disappointed" in PTO's denial, but "we remain confident in our intellectual property." Attorney Kurt R. Karst of Hyman, Phelps & McNamara, writes in the FDA Law Blog Jan. 4 that AstraZeneca will likely contest PTO's decision in court. He adds in a Jan. 7 interview that the denial "could mean earlier generics" in the PPI market "but we don't know at this point." Private-label OTC PPIs emerged in 2008 after Prilosec OTC lost market exclusivity (1"The Tan Sheet" Aug. 11, 2008, p. 3)

You may also be interested in...



Despite Prilosec OTC Weakness, P&G Grows With Price Hikes, Cost Cuts

Procter & Gamble's Prilosec OTC business felt the heat of private-label competition during the firm's latest quarter, the first full period since the brand lost market exclusivity as an OTC proton pump inhibitor

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

Topics

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel